Federal Court Affirmed Ruling Against Truinject Corp.
The ruling ends a legal battle for healthcare operators over trade secrets and contract disputes.
Updated on Oct. 1, 2026 in Healthcare
The US Court of Appeals for the Federal Circuit has upheld a district court judgment against Truinject Corp. regarding claims of trade-secret theft and contract breaches. The decision brings finality to litigation involving contract interference and intellectual property rights.
Why it matters
The ruling reinforces the importance of procedural rigor in court filings, as the appellate panel dismissed the appeal because the company failed to raise key arguments at the trial level. This serves as a reminder for firms that tactical legal oversights at the district court phase can be fatal to long-term litigation outcomes.
The appellate panel upheld a series of district court rulings issued over four years from 2020 to 2024. The decision concludes a legal dispute between California-based Truinject Corp. and Galderma SA.
The players
Truinject Corp.
A California-based company involved in healthcare-related intellectual property and business litigation.
Galderma SA.
An international pharmaceutical company specializing in dermatological products and medical solutions.
US Court of Appeals for the Federal Circuit
The federal court with specialized jurisdiction over patent law and international trade matters.
The details
The US Court of Appeals for the Federal Circuit determined that Truinject Corp. forfeited its claims by failing to present necessary arguments before the Delaware district court. The original case centered on allegations of contract breaches, trade-secret misappropriation, and interference with a business deal. By failing to preserve these arguments in the lower court, the company lost its ability to secure a reversal on appeal.
Timeline
The district court issued initial rulings in 2020, 2023, and 2024.
The US Court of Appeals for the Federal Circuit issued the final affirmance on October 1, 2026.
Market Landscape
The ruling marks the final conclusion of the 2020, 2023, and 2024 Delaware district court judgments. It underscores a trend where appellate courts strictly enforce the requirement that all substantive legal arguments be preserved at the trial level.
Operators should review their litigation strategies to ensure that all material arguments are documented in trial court records to avoid forfeiture on appeal. Relying on outside counsel to maintain a comprehensive and preserved trial record is a standard risk-management necessity.
The takeaway
The appellate defeat highlights the cost of procedural errors when litigating complex commercial disputes. Owners should treat every trial court filing as the primary opportunity to establish the record, as appellate review is restricted to arguments already presented.
Further reading
For more on industry legal shifts, see the Healthcare section.
